This 2020 electron microscope image provided by the National Institute of Allergy and Infectious Diseases - Rocky Mountain Laboratories shows SARS-CoV-2 virus particles which cause COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in a lab. According to a study released in The Lancet Global Health on Wednesday, Oct. 27, 2021, Fluvoxamine, a cheap antidepressant, reduced the need for hospitalization among high-risk adults with COVID-19. (NIAID-RML via AP)
By Carla K. Johnson
A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus.
Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies.
They've shared the results with the U.S. National Institutes of Health, which publishes treatment guidelines, and they hope for a World Health Organization recommendation.
“If WHO recommends this, you will see it widely taken up,” said study co-author Dr. Edward Mills of McMaster University in Hamilton, Ontario, adding that many poor nations have the drug readily available. “We hope it will lead to a lot of lives saved.”
The pill, called fluvoxamine, would cost $4 for a course of COVID-19 treatment. By comparison, antibody IV treatments cost about $2,000 and Merck's experimental antiviral pill for COVID-19 is about $700 per course. Some experts predict various treatments eventually will be used in combination to fight the coronavirus.
Researchers tested the antidepressant in nearly 1,500 Brazilians recently infected with coronavirus who were at risk of severe illness because of other health problems, such as diabetes. About half took the antidepressant at home for 10 days, the rest got dummy pills. They were tracked for four weeks to see who landed in the hospital or spent extended time in an emergency room when hospitals were full.
In the group that took the drug, 11% needed hospitalization or an extended ER stay, compared to 16% of those on dummy pills.
The results, published Wednesday in the journal Lancet Global Health, were so strong that independent experts monitoring the study recommended stopping it early because the results were clear.
Questions remain about the best dosing, whether lower risk patients might also benefit and whether the pill should be combined with other treatments.
The larger project looked at eight existing drugs to see if they could work against the pandemic virus. The project is still testing a hepatitis drug, but all the others — including metformin, hydroxychloroquine and ivermectin — haven't panned out.
The cheap generic and Merck's COVID-19 pill work in different ways and “may be complementary,” said Dr. Paul Sax of Brigham and Women’s Hospital and Harvard Medical School, who was not involved in the study. Earlier this month, Merck asked regulators in the U.S. and Europe to authorize its antiviral pill.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
For the first time microplastics have been found deep in the lungs of living humans. The trace materials potentially came from everyday items such as plastic bottles and bags. Dr. Jessica Shepherd, the chief medical officer at Verywell Health, joined Cheddar News to talk about the report's findings and to discuss the possible risks people might face. "The study’s most important part is we need to decrease our pollution, and we need to think about different ways to consume outside of plastic," she said.
An estimated five billion people lack access to affordable and safe surgical care around the world. For World Health Day, Cheddar News spoke with Kristie Magee Porcaro of Operation Smile, a nonprofit organization assisting with cleft lip and palate surgeries, about how they work to better it around the globe.
There has been notable disagreement in the medical community about a fourth COVID-19 vaccine dose. The FDA last week authorized a second booster dose for older and immunocompromised individuals, as some agency officials did not support the idea. The FDA made the decision without meeting with its advisory committee, as it had ahead of its recommendations on the previous COVID-19 vaccine doses.
The CDC followed in the footsteps of the FDA and authorized a fourth dose as well. Reports say the agency also did not discuss the move with its own advisory team of vaccine experts. Now, a growing number of doctors are speaking out against the decisions - leaving people confused about whether they should get another vaccine dose. Dr. Julie Morita, a member of the CDC's advisory committee to the director, and the executive vice president of the Robert Wood Johnson Foundation, joins Cheddar News' Closing Bell to discuss.
Talmon Marco, CEO of H2Pro, joins Cheddar Innovates to discuss how to bring environmentally friendly hydrogen to scale, and what this means for hydrogen's many use cases.
Catching you up on what you need to know on April 7, 2022, with updates on Ukraine urging NATO for military aid for their war with Russia, the SEC investigating Amazon, microplastics being found deep inside human lungs for the first time, and more.
Patients who have grown frustrated with lingering COVID-19 symptoms and unanswered questions are now not only the subjects of "long covid" research, but also partners in pushing this research forward. Harlan Krumholz, professor of medicine at Yale University, joins Cheddar News to discuss.
A record number of tornadoes were observed in March, topping the previous record set last year. Cheddar News speaks with NOAA’s Harold Brooks about what the implications are of an early tornado season.
Catching you up on what you need to know on April 6, 2022, with updates on the FDA’s meeting to discuss a second COVID booster shot, more on the war in Ukraine, tornadoes on the Gulf coast, a third suspect arrested in connection to the mass shooting in California, Darwin’s lost notebooks mysteriously returned, and more.
Two of naturalist Charles Darwin’s notebooks that were reported stolen from Cambridge University have been returned, two decades after they disappeared.
